Podcasts about London Health Sciences Centre

Dr. Luciano Sposato is the Head of the Southwestern Ontario Regional Stroke Centre at London Health Sciences Centre and talked with 980 CFPL's Mike Stubbs about a new finding in stroke treatment that could have a major impact for stroke patients.

Date: May 14, 2025 Guest Skeptic: Dr. Ross Prager is an Intensivist at the London Health Sciences Centre and an adjunct professor at Western University. His expertise in critical care medicine is complemented by his research interests in critical care ultrasound and evidence-based knowledge translation. This is an SGEM Xtra episode. The inspiration was a […] The post SGEM Xtra: Ten Lessons They Don't Teach in Medical School (But Should) first appeared on The Skeptics Guide to Emergency Medicine.

Guest: Dr. Brian Rotenberg, an otolaryngology specialist and sleep surgeon at London Health Sciences Centre, St. Joseph's Health Care London and Western University.

Date: February 11, 2025 Guest Skeptic: Dr. Ross Prager is an Intensivist at the London Health Sciences Centre and an adjunct professor at Western University. His expertise in critical care medicine is complemented by his research interests in critical care ultrasound and evidence-based knowledge translation. This is another SGEM Xtra. On today's episode, we're diving […] The post SGEM Xtra: Rock, Robot Rock – AI for Clinical Research first appeared on The Skeptics Guide to Emergency Medicine.

Ontario Minister of Health Sylvia Jones spoke with 980 CFPL's Mike Stubbs about family medicine in the province, organization of your health information and an expansion to the Nazem Kadri Surgical Centre at the London Health Sciences Centre.

Editor-in-Chief Dr. Sue Yom hosts Dr. Mai Anh Huynh, Assistant Professor of Radiation Oncology at the Brigham and Women's Hospital / Dana-Farber Cancer Center who wrote an editorial this month, "The Hidden Benefits of Palliative Radiotherapy: When Radiation of Metastatic Disease is Not "Just" Palliative," Dr. David Palma, a Radiation Oncologist at the London Health Sciences Centre who co-authored, "Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase I Study of Stereotactic Ablative Radiotherapy for Poly-metastatic Disease", and Dr. Ethan Ludmir, Assistant Professor in the Departments of Gastrointestinal Radiation Oncology and Biostatistics at the University of Texas MD Anderson Cancer Center and supervising author of "Off-Protocol Radiotherapy in Phase III Metastatic Solid Tumor Trials." The group also discusses an article from this month's issue, "Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?"

Host Rachel Gilbert spoke with LFP reporter Jennifer Bieman about the police probe that has been launched at London Health Sciences Centre, which sources say includes "multiple individuals."

The CEO of the Registered Nurses Association of Ontario, Dr. Doris Grinspun joined 980 CFPL to talk about changes at London Health Sciences Centre and the use and cost of nursing agencies.

The founder and co-director of the London Health Coalition, Peter Bergmanis joined 980 CFPL's Mike Stubbs to share his thoughts on the resignation of the Board of Directors at the London Health Sciences Centre and the use of agencies in health care.

In this episode of Hart2Heart, Dr. Mike Hart sits down with addiction specialist from London, Ontario, Dr. Sharon Koivu. Dr. Koivu offers a unique perspective on the origins and consequences of ‘Safe Supply' initiatives, which were initially introduced to combat the opioid crisis. They discuss the complexities of addiction medicine, the unintended consequences of ‘Safe Supply' programs, and the urgent need to regain focus on the four pillars to approach addiction: harm reduction, treatment, prevention, and enforcement.  Guest Bio and Links: Dr. Sharon Koivu is an Addiction Medicine Consultant for both London Health Sciences Centre and St. Thomas Elgin General Hospital. She has practiced addiction medicine and palliative care in a number of settings over the past 20 years. Dr. Koivu enjoys teaching, has been involved in research projects on infectious complications of injection drug use, and is committed to harm reduction and advocacy for meaningful change. Resources/ Glossary of Terms: Safe Supply Program: A harm reduction approach where regulated opioids are prescribed to individuals with substance use disorders to prevent the harms associated with unregulated street drugs. Hydromorph Contin: A long-acting opioid, previously used as a substitute for OxyContin, known to cause significant complications when injected. Dilaudid: A brand name for hydromorphone, an opioid used for pain management, now commonly prescribed in Safe Supply programs. Dr. Sharon Koivu: 'Safe supply' has only worsened the addiction crisis in London, Ont. Show Notes: (0:00) Welcome back to the Hart2Heart Podcast with Dr. Mike Hart    (0:15) Dr. Hart introduces guest, Dr. Sharon Koivu to the listeners  (1:30) Dr. Koivu gives a brief introduction of herself  (4:00) Intro and intention behind the Safe Supply program (8:45) Dr. Koivu explains the unexpected rise in severe infections due to Safe Supply (12:30) The link between opioid diversion from Safe Supply and organized crime (15:00) The data speaks - increasing opioid use (21:00) Police data of how many dilaudid have been seized off the streets  (27:30) Safe Supply's impact on the youth and the rise of fentanyl use (31:00) Psychological and social effects of opioid addiction on youth (35:30) The challenges faced by healthcare providers in managing patients on Safe Supply (41:00) “So, essentially, dilaudid or D8s, they are more or less like a gateway drug to fentanyl.” (43:00) Opioid use and effects on the developing brain  (48:00) Four Pillars to help with addiction (51:00) CPSO does not monitor Safe Supply prescribers  (56:30) Supervised injection sites and consumption sites   (1:03:00) 2023 Paper of The SOS Program (1:11:00) The need for comprehensive addiction treatment (1:15:30) Closing thoughts --- Dr. Mike Hart is a Cannabis Physician and Lifestyle Strategist. In April 2014, Dr. Hart became the first physician in London, Ontario to open a cannabis clinic. While Dr. Hart continues to treat patients at his clinic, his primary focus has shifted to correcting the medical cannabis educational gap that exists in the medical community.  Connect on social with Dr. Mike Hart: Social Links: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

Virtual Urgent Care is changing demands on Emergency Rooms in Ontario. 980 CFPL's Mike Stubbs sat down with Dr. Rod Lim - the Section Head of the Paediatric Emergency Department at the Children's Hospital at London Health Sciences Centre to talk about the current state of the Emergency department at Children's Hospital and what is now available anyone who may want or need to speak with a doctor.

London Health Sciences Centre is dealing with a budget deficit of $78.1 million dollars. What does that mean for services and front line workers as they move to bring it down? Mike Stubbs sat down with acting president and CEO of LHSC, David Musaj, to discuss those issues and more.

BUFFALO, NY- June 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.” Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. In this new study, researchers Scott Strum, Mark Vincent, Meghan Gipson, Eric McArthur, and Daniel Breadner from the Schulich School of Medicine and Dentistry, London Health Sciences Centre, and Royal College of Surgeons in Ireland analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. “The aim of this retrospective study was to provide additional evidence for the clinical use of conventional serum tumor markers CEA, CA19-9, and CA-125 in NSCLC management.” It constituted a single-center study of NSCLC patients treated with systemic therapy at the London Regional Cancer Program. Serum tumor markers were analyzed for differences in radiographic responses (RECIST v1.1 or iRECIST), associations with clinical characteristics, and all-cause mortality. A total of 533 NSCLC patients were screened, of which 165 met inclusion criteria. A subset of 92 patients had paired tumor markers and radiographic scans. From the latter population, median (IQR) fold-change from nadir to progression was 2.13 (IQR 1.24–3.02; p < 0.001) for CEA, 1.46 (IQR 1.13–2.18; p < 0.001) for CA19-9, and 1.53 (IQR 0.96–2.12; p < 0.001) for CA-125. Median (IQR) fold-change from baseline to radiographic response was 0.50 (IQR 0.27, 0.95; p < 0.001) for CEA, 1.08 (IQR 0.74, 1.61; p = 0.99) for CA19-9, and 0.47 (IQR 0.18, 1.26; p = 0.008) for CA-125. “In conclusion, tumor markers are positioned to be used as adjunct tools in clinical decision making, especially for their associations with radiographic response (CEA/CA-125) or progression (CEA/CA-125/CA-19-9).” DOI - https://doi.org/10.18632/oncotarget.28566 Correspondence to - Daniel Breadner - daniel.breadner@lhsc.on.ca Video short - https://www.youtube.com/watch?v=8LO-Hn0fbrg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28566 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, tumor marker, biomarker, lung cancer; NSCLC, translational research About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Guidelines call for better evidence on the health outcomes after living kidney donation. Author Amit X. Garg, MD, PhD, London Health Sciences Centre, and editorialist Elizabeth C. Lorenz, MD, Baylor College of Medicine, discuss a new study that compares the risks of hypertension and other health outcomes in living kidney donors, with JAMA Associate Editor Wolfgang Winkelmayer, MD, ScD. Related Content: Hypertension and Kidney Function After Living Kidney Donation Prospectively Examining Outcomes After Living Kidney Donation Kidney Transplant Outcomes From Deceased Donors Who Received Dialysis Expanding the Overton Window in Deceased Kidney Donor Eligibility—Enough to Make a Difference?

Jennifer Mannion, Registered Polysomnographic Technician at London Health Sciences Centre, joins 980 CFPL's Mike Stubbs to talk about everything you need to know about going to sleep clinic, starting with what you need to wear.

Editor-in-Chief Sue Yom hosts Dr. Karin Lindberg, a Clinical Oncologist at the Karolinska Institute in Sweden and the supervising author of a new paper this month, "Expanded HILUS trial - a pooled analysis of risk factors for toxicity from SBRT of central and ultra-central lung tumors," and Dr. David Palma, a Radiation Oncologist at the London Health Sciences Centre who co-authored the accompanying editorial, "Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultra-Central Thoracic Tumors?" Dr. Palma also describes the design and findings of the new clinical trial SUNSET, which he presented in the Multidisciplinary Thoracic Cancer Symposium plenary session simultaneously with this podcast release.

Host Rachel Gilbert spoke with LFP health reporter Jennifer Bieman about her recent stories uncovering details of the $470,000 approved for London Health Sciences Centre hospital executives to travel to overseas conferences.

Dr. Raj Gupta from Vanderbilt University Medical Center in Nashville, TN discusses the importance of regional anesthesia and pain management for pediatric surgical cases.  His guests are Dr. Michelle Kars from Northwell Cohen Children's Medical Center  in New York and Dr. Abhijit Biswas from London Health Sciences Centre and St. Joseph's Hospital, Western University, London, Ontario.Twitter: @ASRA_Society, @dr_rajgupta

Host Rachel Gilbert spoke with LFP reporter Jennifer Bieman about the story she broke on the split that looms between London's two hospitals, London Health Sciences Centre and St. Joseph's Health Care, and what it might mean for patients and the community.

Dr. Jackie Schleiffer-Taylor, President and CEO of London Health Sciences Centre joins 980 CFPL's Mike Stubbs to talk about the recent separation of LHSC and St Joseph's Health Care London.

Dr. Douglas Fraser is a scientist with the Lawson Health Research Institute and a critical care physician at London Health Sciences Centre.

Dr. Douglas Fraser is a scientist with the Lawson Health Research Institute and a critical care physician at London Health Sciences Centre.

A new approach promises to increase organ transplants but some question whether they should proceed without revisiting the definition of death, and what happens to rural lands when people head to urban centers   First up this week, innovations in organ transplantation lead to ethical debates. Host Sarah Crespi talks with Staff Writer Jennifer Couzin-Frankel and several transplant surgeons and doctors about defining death, technically. Also in this segment: Anji Wall, abdominal transplant surgeon and bioethicist at Baylor University Medical Center Marat Slessarav, consultant intensivist and donation physician at the London Health Sciences Centre and assistant professor in the department of medicine at Western University Nader Moazami, surgical head of heart transplantation at New York University Langone Health   Next up, what happens to abandoned rural lands when people leave the countryside for cities? Producer Kevin McLean talks with Gergana Daskalova, a Schmidt Science Fellow in the Biodiversity, Ecology, and Conservation group at the International Institute for Applied Systems Analysis, about how the end of human activities in these places can lead to opportunities for biodiversity.   This week's episode was produced with help from Podigy. Additional music provided by Looperman.com   About the Science Podcast   [Image: Martin Cathrae/Flickr; Music: Jeffrey Cook]   [alt: partially collapsed old barn with podcast overlay]   Authors: Sarah Crespi; Kevin McLean; Jennifer Couzin-Frankel   Episode page: https://www.science.org/doi/10.1126/science.adi6336See omnystudio.com/listener for privacy information.

A new approach promises to increase organ transplants but some question whether they should proceed without revisiting the definition of death, and what happens to rural lands when people head to urban centers   First up this week, innovations in organ transplantation lead to ethical debates. Host Sarah Crespi talks with Staff Writer Jennifer Couzin-Frankel and several transplant surgeons and doctors about defining death, technically. Also in this segment: Anji Wall, abdominal transplant surgeon and bioethicist at Baylor University Medical Center Marat Slessarav, consultant intensivist and donation physician at the London Health Sciences Centre and assistant professor in the department of medicine at Western University Nader Moazami, surgical head of heart transplantation at New York University Langone Health   Next up, what happens to abandoned rural lands when people leave the countryside for cities? Producer Kevin McLean talks with Gergana Daskalova, a Schmidt Science Fellow in the Biodiversity, Ecology, and Conservation group at the International Institute for Applied Systems Analysis, about how the end of human activities in these places can lead to opportunities for biodiversity.   This week's episode was produced with help from Podigy. Additional music provided by Looperman.com   About the Science Podcast   [Image: Martin Cathrae/Flickr; Music: Jeffrey Cook]   [alt: partially collapsed old barn with podcast overlay]   Authors: Sarah Crespi; Kevin McLean; Jennifer Couzin-Frankel   Episode page: https://www.science.org/doi/10.1126/science.adi6336See omnystudio.com/listener for privacy information.

In collaboration with ROESCG, we introduce a new series, Cancer Careers! Today we're talking with Dr. David Palma, a Radiation Oncologist at London Health Sciences Centre. He takes us through the basics of Stereotactic Body Radiotherapy, and what medical students should know about Radiation Oncology for the years to come. Please provide us feedback on the episode! : https://qfreeaccountssjc1.az1.qualtrics.com/jfe/form/SV_egHOYIJteV0KqOO

Bonnie Wooten, a Registered Nurse and Project Consultant with London Health Sciences Centre joins 980 CFPL's Mike Stubbs to talk about the award-winning Shared Decision Making Program at Children's Hosptial at LHSC, which brings together patients, families, and their health care team to help make key decisions when it comes to their health and treatment.

Dr George Dresser, Physician at London Health Sciences Centre, joins 980 CFPL's Mike Stubbs to talk about seeing the stroke rate and blood pressure climbing as the temperature starts to drop and as we approach holiday season.

Host Rachel Gilbert spoke with LFP reporter Norman De Bono about the long-term $3-billion overhaul planned for London Health Sciences Centre, and what the provincial plan may cost local taxpayers.

As Diabetes Awareness Month 2022 comes to an end, doctors at London Health Sciences Centre say they are seeing a significant rise in type 1 diabetes. Dr. Robert Stein, Children's Hospital Paediatric Endocrinologist joins Mike Stubbs to discuss the rise they're seeing, and also to educate us on the early signs and symptoms to watch out for. 

Medical problems often do not follow a schedule, and it can be frustrating to get them addressed when the next doctor appointment is weeks or months away. It's important to have a plan about what to do for support between clinic appointments. A good first step is to discuss the issue with your health care team and to arrange to have a designated person or point of contact should such a situation arise. Heather Russell, RN, Coordinator of the Parkinson's Foundation Center of Excellence at the London Health Sciences Centre in London, Ontario, Canada, is that person for her clinic. In this episode, she describes how she helps her patients when they have a medical problem related to their Parkinson's disease and their next scheduled clinic visit is some time away.

Brad Campbell, corporate hospital administration executive at London Health Sciences Centre, joins 980 CFPL's Mike Stubbs to talk about LHSC's new master plan and one major area they are focusing on - mental health.

In this episode of the Plant-Based Canada we chat with Dr Alfonsi. Dr. Jeffrey Alfonsi is an engineer and physician specializing in Internal Medicine, Obesity Medicine, Clinical Pharmacology and Toxicology. He serves as the Chief Product and Medical Officers of RX Food. He currently practices at Trillium Health Partners, Cleveland Clinic Canada, and London Health Sciences Centre.Dr. Alfonsi has an interest in the delivery of personalized medicine, and is actively involved in research to develop a model to deliver personalized medicine across Ontario and Canada. He also believes in the power of diet and lifestyle medicine – helping his patients build healthy and sustainable habits when it comes to what they put on their plates.He has maintained his passion for engineering over the years, creating multiple mobile health applications – including RX Food, an app using A.I. to assess patients' daily eating habits – and is currently developing image-processing technologies to identify the nutritional content of foods to better manage chronic diseases. In this episode we discuss:Dr. Alfonsi's interest in engineering and nutrition and how he merges the two How he utilizes lifestyle medicine and plant-based diets with his patientsHow sustainability and personalized medicine plays into his approachHow Dr. Alfonsi developed RX Food, how it works, and how it helps his patientsThe biggest challenges when it comes to educating physicians and patients about the power of lifestyle medicineSocialsDr. Alfonsi's TwitterRX FoodAI Twitter StudiesCarbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetesFermented-food diet increases microbiome diversity, decreases inflammatory proteins, study finds 

Pediatric ICU capacity is at or beyond its limits, and parents aren't far behind. Why is illness on the rise for kids across the province? For insight we welcome: Dr. Rod Lim, Site-Chief of the Paediatric Emergency Department at the Children's Hospital at London Health Sciences Centre, and an associate professor at Western University; and former director of the COVID-19 Science Advisory Table, Dr. Fahad Razak, who is an internist at St Michael's Hospital and assistant professor at the University of Toronto.See omnystudio.com/listener for privacy information.

Mark Towhey speaks with a former MMA fighter about UFC's new combat sport venture, "slap fighting." Why has it become a topic of controversy?  On today's show:  A conversation with Dan Hardy, an English former mixed martial artist, on UFC's recently-approved “Power Slap League." Dr. Abdel-Rahman Lawendy, chief and medical director of the ambulatory surgical centre at London Health Sciences Centre, on reimagining the operating room to reduce surgery wait times.  Gavin Tighe, a senior partner with Gardiner Roberts LLP, on Premier Doug Ford's government challenging his summons to appear at the Emergencies Act inquiry. Richard Carlson, Director of Energy at Pollution Probe, on whether nuclear energy is the bright green future for Canada. Retired Major-General David Fraser on what "dirty bombs” are and why Russia keeps talking about them.

Host Rachel Gilbert and LFP health care reporter Jennifer Bieman discuss the deepening wait-time troubles at London Health Sciences Centre, whose officials are urging people to consider not going to the ER unless absolutely necessary.

Elizabeth Phoenix, Nurse Practitioner at the Adult Eating Disorder Service at the London Health Sciences Centre joins 980CFPL's Mike Stubbs to talk about the 10-year milestone of the program, as well as how many people the AEDS has helped over the past 10 years.

Good Donation, Faheem & Nelly J start the episode discussing the recent announcement that the WNBA will hold the 1st exhibition game outside US soil in over a decade in Toronto, how the game will be received and some obstacles the WNBA may have with a Toronto expansion. We then discuss both the NBA's new changes of lowering the age limit to 18 and the new policies to assist players with mental health. We then highlight Nazem Kadri (NHL player, Calgary Flames) in our FOR THE CULTURE segment where we discuss his $1M donation in support of Ambulatory Surgical Centre at London Health Sciences Centre. It will now be known as Nazem Kadri Surgical Centre. We then conclude episode 110 with THAT'S ABSURD to discuss NBA fines Minnesota Timberwolves star Anthony Edwards $40K for anti-gay comments on social media. Please comment and share your thoughts, thanks for taking the time to watch or listen to the episode GOOD ROOKIES. DO GOOD and BE GOOD. Do you have a great topic suggestion? Please email us goodrookiespodcast@gmail.com Get alerts when we drop new episodes by subscribing and turning on your alerts. :)

Sarah Smith, Manager of Nursing Professional Practice at London Health Sciences Centre and Jose Villamater, an internationally educated nurse at LHSC join Mike Stubbs to talk about the provincial government approving changes that allow internationally trained nurses to start practicing at health care organizations sooner with the goal of alleviating staffing shortages.

Dr. Bill Wall is one of the pioneers of liver transplantation, especially in Canada. We spoke to him on this episode about his training, the early days of transplantation and about his new children's book! Links: 1. Member of the Order of Canada: https://www.gg.ca/en/honours/recipients/146-9121 Bio (from https://www.gg.ca/en/honours/recipients/146-9121) William Wall is a dedicated and compassionate physician whose surgical and clinical proficiency have benefited many Canadians with end-stage organ disease. Professor of surgery at the University of Western Ontario, he established Canada's first liver transplant program at the London Health Sciences Centre, where he is director of the Multi-Organ Transplant Program. In this role, he has promoted excellence in research and patient care, as well as public awareness and support for organ donation. Widely respected by his peers, he served as president of the International Liver Transplantation Society.

“It's going to happen. It's a normal part of infant development; it's neither the fault of the parent or caregiver, or the baby.” Your baby's incessant crying is difficult to endure, and it's important to remember that the period of PURPLE Crying has a beginning — and an end. Utilize five coping and soothing components that can help prevent Shaken Baby Syndrome or Abusive Head Trauma. Learn more at dontshake.org.Kat Jacobs, MSc, Injury Prevention Specialist, Victoria Hospital, Trauma Program, London Health Sciences Centre.

Welcome to the first episode of IMPACT Medicom's podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas. This episode includes a discussion of:The role of the pathologist in the management of head and neck cancers PD-L1 testing as a predictive biomarker for immunotherapy in HNSCCImproving the testing process for PD-L1 Our Guest:Our guest is Dr. Matthew Cecchini, Pathologist in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre and  Assistant Professor at Western University in London Ontario Canada. Dr. Cecchini  specializes in pulmonary, head and neck, and molecular pathology. His research interests include the application of digital and machine learning tools in pathology. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

Continuing our special series, What's New In: Dr. Wheatley Price discusses new advances in Radiotherapy with Dr. Corinne Faivre-Finn of the NHS Foundation Trust and Dr. David Palma of the London Health Sciences Centre. This webinar aired on December 1, 2021,

Libby Znaimer is joined by Karen Stintz, CEO of Variety Village, John Capobianco, Senior Vice President & Senior Partner, FleishmanHillard HighRoad,

Inspiring and engaging is what describes Ioanna inside this Podcast. A very talented footballer who had stroke on the field of play in July of 2021. A huge shout out to the quick actions of many at the field and the Pediatric Critical Care Doctors at London Health Sciences Centre. Due to their knowledge and actions of performing a unique surgical application Ioanna was on the road to recovery within weeks of this life changing moment. She inspired the soccer community from all over the country. "The Pink Shirt" fundraiser was a tremendous success. Total funds raised: $17,594.31. Thank you to everyone that supported the Pink T-Shirts, our club and Ioanna's road to recovery. A breakdown of donations: Online Donations - $2,420.00 Sobey's Canada - PCCU - $5,000.00 Sobey's Canada - Vanier Crisis Management Services - $5,000.00 Pink T-Shirt - $5, 174.31

Show notes at: www.naileditortho.com/proximalhumerus  Listen to our episode on Proximal Humerus Fractures as Dr. Strelzow gives us an excellent overview!  Dr. Strelzow specializes in the treatment of complicated fractures and post-traumatic deformities, such as complex periarticular injuries and hand injuries. He also specializes in upper extremity arthroscopy and arthroscopy-assisted fracture treatment. Also, he is an expert in orthopaedic trauma, treats patients with fractures and injuries, with a focus on trauma to the upper extremities, especially the hand. He is now conducting research on patient-reported outcomes linked to elbow injuries, shoulder trauma, and complete elbow replacements, in addition to his clinical work.  In addition, he is particularly interested in assessing the functional outcomes of urban trauma, with the objective of improving patient treatment and resuming regular activity.Moreover, Dr. Strelzow completed his medical degree and residency at the University of British Columbia Faculty of Medicine, and later his fellowship at London Health Sciences Centre; Royal Infirmary of Edinburgh. Goal of episode: To develop a baseline knowledge on Proximal Humerus Fractures. We cover: PE Xray CT Classification Pathoanatomy Vascularity AVN risk Common approaches Treatment R TSA Implant Fixation Reduction + implant techniques Complications

Researchers out of Lawson Health Research Institute and Western University' Schulich School of Medicine and Dentistry will be examining the impacts of what's known as “moral injury” on the brains of health-care workers amid the COVID-19 pandemic. A moral injury involves injury to a person's moral conscience and can happen when someone sees or does something, or fails to prevent something, that conflicts with their morals. As a result, people are often left with profound guilt and shame. Dr. Ruth Lanius, associate scientist at Lawson, Schulich professor and London Health Sciences Centre psychiatrist, joins Mike Stubbs to discuss. See omnystudio.com/listener for privacy information.

Show notes at: www.naileditortho.com/proximalhumerus  Listen to our episode on Proximal Humerus Fractures as Dr. Strelzow gives us an excellent overview!  Dr. Strelzow specializes in the treatment of complicated fractures and post-traumatic deformities, such as complex periarticular injuries and hand injuries. He also specializes in upper extremity arthroscopy and arthroscopy-assisted fracture treatment. Also, he is an expert in orthopaedic trauma, treats patients with fractures and injuries, with a focus on trauma to the upper extremities, especially the hand. He is now conducting research on patient-reported outcomes linked to elbow injuries, shoulder trauma, and complete elbow replacements, in addition to his clinical work.  In addition, he is particularly interested in assessing the functional outcomes of urban trauma, with the objective of improving patient treatment and resuming regular activity.Moreover, Dr. Strelzow completed his medical degree and residency at the University of British Columbia Faculty of Medicine, and later his fellowship at London Health Sciences Centre; Royal Infirmary of Edinburgh. Goal of episode: To develop a baseline knowledge on Proximal Humerus Fractures. We cover: PE Xray CT Classification Pathoanatomy Vascularity AVN risk Common approaches Treatment R TSA Implant Fixation Reduction + implant techniques Complications

An interview with Dr. Muriel Brackstone from London Health Sciences Centre and Dr. Tari King from Dana Farber and Brigham and Women's Cancer Center, authors on “Management of the Axilla in Early-Stage Breast Cancer: OH (CCO) and ASCO Guideline.” This guideline addresses management & timing of surgical and radiotherapeutic treatment of the axilla in early breast cancer. Read the guideline at asco.org/breast-cancer-guidelines. Suggest a topic for guideline development at surveymonkey.com/r/ascoguidelinesurvey.

In today's episode I sit down with author and internationally recognized trauma researcher, Dr. Ruth Lanius. Dr. Lanius is an absolute wealth of information and a pioneer in the field of Mind-Body medicine. Join us as we talk about how to stay with intense emotions, the difference between remembering past traumas versus re-living them, how anger can be used as a tool to heal and so much more. Highlights: Discover the difference between big “T” and little “t” traumas. Learn how the brain physiologically changes due to trauma and how this helps to direct treatment. Understand the importance of expressing emotion and growing up in a home that allowed for the expression of emotion. Discovering how anger can actually be used to heal. How does one develop optimal emotional regulation? Discover how import our attachment relationships are between the ages of 0-3. Learn about the five dimensions of trauma. Contact: Dr. Ruth Lanius, M.D., Ph.D. London Health Sciences Centre 339 Windermere Rd., PO Box 5339 London, Ontario N6A 5A5 Canada Tel: (519) 663-3306 Fax: (519) 663-3927 E-mail: ruth.lanius@lhsc.on.ca  

Hosts Jack West and Charu Aggarwal speak with radiation oncology experts David Palma of the London Health Sciences Centre and Puneeth Iyengar of University of Texas-Southwestern about the functional definition and treatment of oligometastatic cancer.

Greenwood Genetics Center’s Ray Louie and Kellie Walden join the show to discuss epigenetics. Dr. Ray Louie is an Assistant Director in Greenwood’s Molecular Diagnostic Laboratory. His background is in large scale genetic screening in model organisms and in solid tumor genetics and radiobiology. Dr. Louie is interested in the diagnosis of Mendelian disorders and in the identification of novel genes involved in neurodevelopmental delay and hydrops fetalis.Kellie Walden is Greenwood’s Director of Diagnostic Development and a genetic counselor by training. She oversees areas of growth for the labs including new test offerings and industry contracts. She also continues to be involved in marketing activities for the Diagnostic Lab. Kellie is a member of the National Society of Genetic Counselors.EpiSign is the first clinical assay validated to detect unique epigenetic signatures and methylation abnormalities for recognized genetic conditions. Right now, EpiSign tests for over 40 conditions that have signatures. Version 3 will be launching in the spring with even more conditions! This test was developed by London Health Sciences Centre in Ontario, and our lab at the Greenwood Genetic Center performs the bench work and the data is analyzed by the team in Canada. The National Human Genome Research Institute named EpiSign one of the 10 most significant advances in genomic medicine in 2019!On This Episode We Discuss:Defining epigeneticsEpigenetic disorders (Prader–Willi, Angelman, Beckwith-Wiedemann syndrome)Testing for epigenetic conditions through EpiSignIndications to order epigenetic testingVariant of Uncertain Significance (VUS) clarification with EpiSignCurrent research on epigenetic conditions New versions of EpiSignCalculating biological age with epigenetics Learn more about Greenwood Genetic Center’s EpiSign here. You can also check out their incredibly popular genetic counseling visual aids. Enter our giveaway on Instagram, Twitter, Facebook, and LinkedIn to win a pair of bluetooth, noise canceling headphones from Greenwood. Giveaway ends on April 11th. Ray and Kellie showcased how complex pediatric genetics can be, so it’s understandable that people are often confused about the role genetics play in health conditions. The genetic counselors over at Advanced Tele-Genetic Counseling (ATGC) specialize in areas of genetics like pediatrics. So if you find yourself having questions about your own genetics, or want to know more about adding the expertise of AT-GC’s certified genetic counselors to help support your own practice, reach at AT-GC.com. You can also hear Elizabeth Turner on Episode #143 where she shares more about telehealth and what ATGC has to offer. Stay tuned for the next episode of DNA Today on April 16th, which explores whole exome sequencing with QuantGene’s Jo Bhakdi! New episodes are released on the first and third Friday of the month. In the meantime, you can binge over 140 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Brand new in 2021, episodes are now also recorded with video which you can watch on our YouTube channel. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com.

About the Show: Today I speak with Dr. Agnes Wainman, a clinical psychologist that helps overwhelmed and worried women overcome unrealistic expectations that are making them sick and miserable. She coined a term called Expectation Discrepancy Syndrome.  We talk about: - what causes unrealistic expectations - why they are making you miserable and  - how to overcome them. About Dr. Agnes Wainman: -- I understand what it's like to feel overwhelmed, to face unexpected life stressors and to struggle with finding balance between self-care and the care of everyone else.  I know what it's like to feel like you're doing everything that you "should" do, yet it still never feels like it's enough.  It is exhausting, both physically and emotionally.  I want to help you silence that nagging voice in your head that says that you're not good enough or that you're not doing enough.  I want you to be able to enjoy your life without having to imagine all the possible worst case scenarios and feeling like you need a contingency plan for all of them.  My passion is to help you put you back on your own priority list, without guilty or worry. I decided to pursue my PhD in clinical psychology because I have always been intrigued by people, their stories, their relationships, their responses to stressful situations and their resilience. During my studies at Western University in London, Ontario, I was incredibly lucky to have trained in a number of different settings including working with university students at the Student Development Centre, patients with spinal cord injuries at Parkwood Hospital, patients living with chronic pain and other medical conditions at London Health Sciences Centre.  I received training in a number of different theoretical orientations including cognitive behavioral therapy, psychodynamic psychotherapy and mindfulness meditation training. During my residency at the London Clinical Psychology Residency Consortium, I continued my training within programs such as the Fertility Clinic and received specialized training in the relationship between physical health and emotional well-being.  Following the completion of my Doctoral Degree, I began working in private practice and then founded London Psychological Services.  I am so privileged to be invited into your life. -- Connect with Dr. Agnes Wainman: Website: https://www.screwexpectations.com/ Facebook: https://www.facebook.com/dragneswainman Instagram: https://www.instagram.com/screwexpectations/?hl=en

Dr. Christen Shoesmith and Dr. Colleen O’Connell discuss the first Canadian guideline on the care and management of patients with amyotrophic lateral sclerosis (ALS). Dr. Shoesmith and Dr. O'Connell are two of the authors of the guideline, which is intended for ALS clinicians, allied health professionals and primary care providers and includes a patient-focused approach to care, with attention to holistic and emotional aspects of well-being. Dr. Christen Shoesmith is a neurologist and medical director of the Motor Neuron Disease Clinic at London Health Sciences Centre in London, Ontario. She is also chair of the ALS guidelines working group. Dr. Colleen O’Connell is a physical medicine and rehabilitation physician at the Stan Cassidy Rehabilitation Centre in Fredericton, New Brunswick. The clinical practice guideline is published in CMAJ: www.cmaj.ca/lookup/doi/10.1503/cmaj.191721 ----------------------------------- Subscribe to CMAJ Podcasts on Apple Podcasts, iTunes, Google Play, Stitcher, Overcast, Instacast, or your favourite aggregator. You can also follow us directly on our SoundCloud page or you can visit www.cmaj.ca/page/multimedia/podcasts.

Chapter 1: Democratic presidential nominee Joe Biden held his first even with running mate Kamala Harris yesterday as the November election looms.  Guest: Jennifer Johnson, Global News Washington Correspondent. Chapter 2: We know reopening schools is risky and only time will tell whether it's going to lead to outbreaks of COVID-19, but researchers at Western University say the negative impact of NOT reopening schools might be much worse.  Guest: Dr. Michael Silverman, Chief of Infectious Diseases for St. Joseph's Healthcare and the London Health Sciences Centre in London. Chapter 3: Premier John Horgan and health officials in BC have been crystal clear that young people make up the largest cohort of new cases of COVID-19.  Guest:  Steve Joordens, psychology professor at the University of Toronto Scarborough. Chapter 4: Kids are set to return to the classroom on September 10th, education minister Rob Fleming joins us to talk about the pressing questions parents have about how this is all going to work.  Guest: Rob Fleming, BC Education Minister. Chapter 5: Are Canucks fans going to bars to watch playoff hockey?  Any other year, you'd expect bars to be packed with fans eager to watch the Canucks NHL playoff run. But this year will certainly be different.  Guest: Kelly Jordan Hamilton, Sales and Marketing Manager at Red Card Sports Bar & Eatery  Chapter 6: It's a dire situation for the Fraser river sockeye salmon run which is expected to be the worst ever recorded. Guest: Fiona Martens, Chief of Fisheries Management Programs with the Pacific Salmon Commission Chapter 7: Simon Fraser University is changing the name of their athletics teams after hearing the “Clan” was often being associated with racial discrimation because of the KKK. Guest: Andrew Petter, SFU president

This episode is sponsored by the new online course SHIFT.Jill Craven is well known throughout the national healthcare system and has an extensive leadership background. She currently serves as the Chief Executive Officer for the Thames Valley Children's Centre, a regional rehabilitation centre for children and youth with disabilities. Her previous work experience highlights include: Vice President, Pharmacy Services at Mohawk Medbuy Corporation in London; Director of the London Regional Cancer Program at London Health Sciences Centre and Director of Children's Care at Children's Hospital of London Health Sciences Centre. Jill graduated from the Leslie Dean Faculty of Pharmacy at the University of Toronto with a Bachelor of Science in Pharmacy and later received a Master's Degree in Leadership from the University of Guelph. She is a licensed member of the Ontario College of Pharmacists and is Lean Healthcare Certified. Jill's leadership passions include: ensuring the client and family voice is heard to improve client experience; developing others for leadership; enabling and supporting front line staff: evidence and quality based care; and building highly reliable and collaborative teams to support the client and family while being fiscally responsible and quality driven.--- Send in a voice message: https://anchor.fm/deb-crowe/message This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit debcrowe.substack.com

In this episode, we are joined by repeat guests Dr. Morad Hameed (@moradhameed) and Dr. Neil Parry to talk about how surgeons across the country have adapted to COVID. We also talk about the impact COVID has had on final year residents across the country. Finally, we discuss the basics of COVID management. Dr. Morad Hameed is a trauma surgeon and intensivist at the Vancouver General Hospital (VGH) and an Assistant Professor of Surgery at the University of British Columbia (UBC). He is the Head of the UBC and VGH Division of General Surgery and is a Service Chief for Acute Care Surgery at VGH. Dr. Neil Parry joined the staff at London Health Sciences Centre and the Department of Surgery at Western in July 2003 as an Assistant Professor. He was promoted to Associate Professor in July 2010. He has served as the Medical Director of Critical Care, Victoria Hospital, LHSC and is currently the Director of Trauma for London Health Sciences Centre. He has held several leadership roles with the Trauma Association of Canada and is the Provincial Chair of the Committee on Trauma for the American College of Surgeons. Links: 1. SCCM Guide to COVID management for non-intensivists: https://sccm.org/covid19 2. UBC Reticulum. This online platform developed by BC surgeons has been utilized extensively by surgeons across the country to communicate about COVID. https://www.ubcreticulum.com/ 3. CBC News article on cancelled Royal College exams: https://www.cbc.ca/news/canada/hamilton/resident-doctors-certification-covid-1.5510028 4. The Behind the Knife podcast (https://behindtheknife.libsyn.com/) has had some excellent episodes recently on ventilator & COVID management. 5. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (published March 2020) is available https://bit.ly/3dB9H2Z 6. Traumacast also has an excellent episode on the management of COVID. https://open.spotify.com/show/1CnoyxwOXlARa9Kd69zsA) 7. Re-listen to our episode with Dr. Kirkpatrick on telementoring: https://soundcloud.com/cjs-podcast/e06-andy-kirkpatrick

Neil Parry breaks down trauma resuscitation, whole blood in Canada, REBOA, and pelvic packing. We even delve into duodenal and pancreatic trauma! Neil Parry is a practicing trauma surgeon in London Health Sciences Centre in London, Ontario. Link: -Five Things They Don't Teach in You Medical School: https://canjsurg.ca/vol59-issue5/59-5-296/ -Trauma surgery associations and societies: which organizations match your goals?: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065540/

Should you be as scared of coronavirus as the thousands of people wearing surgical face masks would make it seem? Given that the total number of deaths has surpassed the cumulative total of MERS and SARS combined, some would say yes. But there is more to the story than just numbers. In this episode, we chat with Dr. Michael Silverman, Chief of Infectious Diseases at London Health Sciences Centre, about the current state of the NCov epidemic and what kinds of preventative practices can reduce the risk of infection.   

Dr. Karen Bosma, London Health Sciences Centre and lead author of the report published in the Canadian Medical Association Journal talks about first case of near-fatal vaping related injury in Canada

Les completed a BSc (Hon) & DDS at Western followed by a GPR at the London Health Sciences Centre. He maintained a full-time solo private practice with an emphasis on digital dentistry, prosthodontics and medical device research while continuing hospital privileges at Strathroy-Middlesex General. His research was supported by the Scientific Research and Experimental Development Fund and the National Research Council. In 2011, Kalman transitioned to full-time academics as an assistant professor and outreach coordinator. Kalman’s research focuses on medical devices & technologies relevant to clinical dentistry. He has authored close to 40 articles, holds two patents and has translated two technologies. Kalman maintains his position as the founder and President of Research Driven. He is an active member of the Academy of Osseointegration, the International Congress of Oral Implantologists, the Standards Council of Canada and serves on the Board of Directors for the University of Western Ontario Faculty Association and the Canadian Association of Public Health Dentistry. He has been recognized as an Academic Associate Fellow (AAID), Fellow, Master and Diplomate (ICOI), has been awarded the Schulich Alumni of Distinction Award and most recently the Merck Patients First award.

Andre Madison, General Internal Medicine (GIM) fellow at Western University, is back on The Rounds Table with Michael Juba, clinical pharmacist at London Health Sciences Centre in Infectious Disease and Anti-Microbial Stewardship.  Together they are covering the efficacy of ceftazidime-avibactam salvage therapy for Klebsialla pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae and transcatheter mitral-valve repair in heart ... The post Superbugs Going Superbad: Ceftazidime-Avibactam Salvage Therapy for Klebsiella pneumoniae and Transcatheter Mitral-Valve Repair in Heart Failure appeared first on Healthy Debate.

Andre Madison, General Internal Medicine (GIM) fellow at Western University, is back on The Rounds Table with Michael Juba, clinical pharmacist at London Health Sciences Centre in Infectious Disease and Anti-Microbial Stewardship.  Together they are covering the efficacy of ceftazidime-avibactam salvage therapy for Klebsialla pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae and transcatheter mitral-valve repair in heart ...The post Superbugs Going Superbad: Ceftazidime-Avibactam Salvage Therapy for Klebsiella pneumoniae and Transcatheter Mitral-Valve Repair in Heart Failure appeared first on Healthy Debate.

In this podcast, John Marchica discusses the intricacies of Canadian health care with his old colleagues, Trafford Crump, PhD and Paul Woods, MD, MS. Canada’s health care system is about 70% federally funded and is experiencing the same health care trends of an aging population and attempts to move towards a value-based care model. Here are some of the interview highlights: How health care is structured in Canada, and its similarities and differences to health care in the U.S. The increasing costs of health care in Canada, and delving into why this is becoming a trend. The reasonings behind looking to the province of Ontario to lead the way to value-based care in Canada. Speaker Bios Trafford Crump, PhD is a health services researcher and assistant professor at the University of Calgary’s Department of Surgery with an interest in patient-centered measures. Dr. Crump's earlier research involved developing the methods for eliciting health care preferences from community-dwelling Medicare beneficiaries in the United States. Dr. Crump's more recent research has expanded into linking primary data collected from patients with large administrative data sets maintained by regional and provincial health authorities. Dr. Crump is part of a University of British Columbia-led research team – which includes strong collaboration from the Vancouver Coastal Health Authority and the B.C. Ministry of Health – that has undertaken one of the largest systematic collections of patient-reported outcomes (PROs) in Canada. Dr. Crump received his PhD from Dartmouth College in the field of Evaluative Clinical Sciences followed by a postdoctoral fellowship at The University of British Columbia. Paul Woods, MD, MS is the President and CEO of London Health Sciences Centre in London, Ontario, Canada. Dr. Woods began his career as a practicing Family Medicine physician in the United States. After finishing his graduate degree in Evaluative Clinical Sciences from Dartmouth College in 2007, he served in several health care executive positions including as the Medical Director at Essentia Health, Department Chief of Primary Care at Spectrum Health Medical Group, and the interim Medical Director for the Michigan Center for Clinical Systems Improvement. Most recently, from 2014 to 2017, Dr. Woods was the Senior Vice President, Provider Network Organization for Trinity Health – a multi-institutional health care organization comprised of over 120,000 people, including over 7,000 physicians and advanced practice providers, across more than 1,700 sites in the United States. In this role, Dr. Woods had clinical, operational and financial accountability for medical practices in primary care, specialty care and hospital-based physician practices. Dr. Woods received his M.D. from Western University. John Marchica is a veteran health care strategist and CEO of Darwin Research Group. He was the founder and CEO of FaxWatch, a leading business intelligence and medical education company and two-time member of the Inc. 500 list of America's fastest growing companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John earned his B.A. in economics from Knox College, an MBA and M.A. in public policy from The University of Chicago, and completed his Ph.D. coursework and doctoral exams in clinical epidemiology and health economics at The Dartmouth Institute for Health Policy and Clinical Practice. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Support us on Patreon - https://www.patreon.com/QuigginReport Dr. Tarkek Loubani is an emergency physician from London, Ontario. He has worked overseas before in Tanzania and in conflict zones such as Iraq and southern Lebanon. He is a Palestinian but was born in Kuwait before moving to Canada. His father, Mahmoud Loubani, is also a doctor. In addition to working at the London Health Sciences Centre (http://www.cbc.ca/news/canada/london/tarek-loubani-shot-gaza-1.4663694), Dr Tarek Loubani is also an also an associate professor at the University of Western Ontario’s Schulich Medicine & Dentistry School (http://www.schulich.uwo.ca/about/news/2018/may/dr_tarek_loubani_update.html). Of note, in addition to his positions in Canada, he also is an emergency physician at the al-Shifa hospital in Gaza. It is curious to note that of the ten known major hospitals in Gaza, Dr. Tarek Loubani happens to work at the one that has a series of close associations to Hamas. According to a Washington Post report (http://www.algemeiner.com/2014/08/01/finnish-tv-reporter-at-gazas-al-shifa-hospital-its-true-that-rockets-are-launched-here-from-the-gazan-side-into-israel-video/) in 2014, the al-Shifa Hospital "has become a de facto headquarters for Hamas leaders, who can be seen in the hallways and offices." Perhaps Prime Minister Trudeau’s idea for an investigation into the whole event is not such as bad idea. Would such an investigation in Canada reveal other doctors who have supported fund raising for terrorism? Are any of them close to Tarek and Mahmoud Loubani? 1. Document on IRFAN, including information on Dr Mahoud Loubani being a voting member on the board of IRFAN. https://www.globalphilanthropy.ca/images/uploads/Appendix_A_AFL_IRFAN.pdf 2. Major reference website for a variety of documents on the CRA investigation into IRFAN: https://www.globalphilanthropy.ca/blog/international_relief_fund_for_the_afflicted_and_needy_canada_irfan-canada_h 3. The CRA document showing the government’s intention to revoke the charitable status of IRFAN for funding terrorism. https://www.globalphilanthropy.ca/images/uploads/01_20110309_NITR_with_App_A,_B_and_C.pdf 4. A press story on the RCMP raiding the premises of IRFAN in Mississauga and Montreal: RCMP raids Muslim relief group's offices as Canada declares it a terrorist organization, Stewart Bell, 29 April 2014. http://nationalpost.com/news/canada/canada-outlaws-toronto-based-muslim-relief-group-adds-it-to-terrorist-list 5. A press story on the al-Shifa Hospital parking lots being used to fire rockets at Israel. Its True that Rockets Are Launched from here from the Gazan side into Israel. http://www.algemeiner.com/2014/08/01/finnish-tv-reporter-at-gazas-al-shifa-hospital-its-true-that-rockets-are-launched-here-from-the-gazan-side-into-israel-video/ 6. A press story concerning the arrest of Dr. Tarek Loubani being arrested in Egypt. 7. A statement from the Schulich Medicine & Dentistry School concerning Dr. Tarek Loubani. http://www.schulich.uwo.ca/about/news/2018/may/dr_tarek_loubani_update.html (http://www.schulich.uwo.ca/about/news/2018/may/dr_tarek_loubani_update.html%20) 8. CRA website showing members of the board of directors of IRFAN in 2009. http://www.cra-arc.gc.ca/ebci/haip/srch/t3010form21officers-eng.action?b=885408849RR0001&fpe=2009-12-31&n=INTERNATIONAL+RELIEF+FUND+FOR+THE+AFFLICTED+AND+NEEDY+%28CANADA%29 9. CRA website showing members of the board of directors of IRFAN in 2003. http://www.cra-arc.gc.ca/ebci/haip/srch/t3010form18officers-eng.action?b=885408849RR0001&fpe=2003-12-31&n=INTERNATIONAL+RELIEF+FUND+FOR+THE+AFFLICTED+AND+NEEDY+%28CANADA%29 10. CRA website showing members of the board of directors of IRFAN in 2007. http://www.cra-arc.gc.ca/ebci/haip/srch/t3010form19officers-eng.action?b=885408849RR0001&fpe=2007-12-31&n=INTERNATIONAL+RELIEF+FUND+FOR+THE+AFFLICTED+AND+NEEDY+%28CANADA%29

Welcome to another episode of Biotechnology Focus radio. I am your host – Michelle Currie – here to give you the rundown on the Canadian biotech scene. This week I’ll be discussing how the regenerative medicine community is abuzz, expanding personalized medicine, and the very recent announcement from the Ontario government that brings great news to the life sciences sector.   +++++  The regenerative medicine field, which includes cell and gene therapies (CGTs), is still abuzz with the fall approvals of three CGTs by the U.S. Food and Drug Administration: Novartis’ Kymriah, Gilead/Kite Pharma’s Yescarta and Spark Therapeutics Inc.’s Luxturna.  At the Cell and Gene Therapy World conference in Miami, Florida (January 22-25), many of the talks were either about the approved treatments or congratulating the industry on these significant milestones.  Reni Benjamin, of Raymond James Financial, reminded delegates that the pharmaceutical industry is also feeling confident about cell and gene therapes s. Acquisitions in 2017 were worth billions: Gilead acquired Kite for $11.9 billion, Takeda bought Ariad for $5.2 billion and Roche acquired Ignyta for $1.7 billion. As the conference was just getting underway, the news was announced that Celgene is buying Juno Therapeutics for $9 billion.  Illustrating the future of the field are the more than 1,300 currently open clinical trials listing stem cells (from sources other than blood) as the primary therapeutic, the 1,000 clinical trials in gene therapy, and clinical trials involving chimeric antigen receptor (CAR) T cells (a type of immune system cell) accounted for around half of clinical trials in 20162.  As such, global investment in the cell and gene therapies and regenerative medicine industry is booming. For example, public and private investment in immuno-oncology has grown to $1.5 billion2. When it comes to gene therapies, the forecast for the year 2025 ranges from $4.3 billion to $10 billion2 due to recent advances in the understanding of genetic disease, and innovation in genetic engineering tools. Altogether, it is estimated that the regenerative medicine industry will explode to a valuation of up to $20 billion by the year 2025.     So, where does Canada sit in terms of being an innovator in these advanced therapeutic technologies?     Let’s start with the good news. Canada is a prominent force in this emerging global field. We have a strong backbone of Canada-based researchers who are recognized scientific leaders, and a robust system for the development of highly-qualified personnel through Canada’s universities. We have also benefited from strategic investments in research, collaborative networks and infrastructure, and are developing a deep understanding of how to translate these advanced therapies from the bench to the bedside.  One way to sustain Canada’s leadership position is to nurture the right skills and education within our borders. Encouraging STEM (science, technology, engineering and mathematics) education from a young age is a necessary first step. Extending STEM-based education with biomedical engineering programs at the university level is a good strategy for supporting the growth of Canada’s CGT and regenerative medicine industry. Biomedical engineering – where engineering design principles and mathematics are applied to medicine and biology, allowing students to make significant contributions to improving human health by finding new diagnostic or therapeutic solutions – is an area Canadian universities are increasingly focusing on.  An illustration of how biomedical engineers are already impacting the regenerative medicine field can be found at the University of Toronto’s Institute of Biomaterials and Biomedical Engineering (IBBME) and at Medicine by Design. The 55-year-old IBBME fosters a multidisciplinary research community where students and investigators in engineering, medicine and dentistry collaborate to develop innovative solutions that address global challenges in human health. Their impact can be seen in the development of breakthrough biomedical devices and new biomaterial products.  Funded in 2015 with a generous federal grant, Medicine by Design builds on IBBME’s successful multidisciplinary model to conceive, create and test strategies to address critical problems in regenerative medicine. By working across disciplines and generating and using emerging methods, like genome editing, computational modelling and synthetic biology, Medicine by Design is generating a deeper understanding of core biological concepts controlling stem cell fate, and devising new therapeutic approaches that will improve health outcomes.  This successful approach is now receiving a significant boost in Vancouver, where the University of British Columbia (UBC) has launched a new School of Biomedical Engineering as a partnership between the Faculty of Medicine and the Faculty of Applied Science.     Centre of commercialization and regenerative medicine, a Toronto-based leader in developing and commercializing regenerative medicine technologies, understands how the intersection of engineering and medicine, introduced by biomedical engineers, can help provide the tools that will advance the industry now and into the future.  One area where Centre of commercialization and regenerative medicine employs biomedical engineers is in its Centre for Advanced Therapeutic Cell Technologies (CATCT), a joint investment by GE Healthcare and the Government of Canada. Biomedical engineers work on process development strategies and solutions, and on projects involving reprogramming and engineering cells, immunotherapies and gene therapies. Operational for over a year, Centre for Advanced Therapeutic Cell Technologies was created to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. The team introduces new technologies to solve emerging technical challenges and closes gaps in current and future workflows.      Our next challenge is to make certain that we have the people, technologies, processes and infrastructure to ensure Canadians have equitable access to these potentially game-changing therapies. Biomedical engineering programs are a start. Engineers are trained to look for efficiencies through cost reductions and improved technologies.  We need to build a Canadian innovation cluster that will attract talent and business expertise to capture the intellectual property developed in Canada and mobilize it for the benefit of Canadians.  We also need to work with government to position our health-care system as part of our competitive advantage. A big part of getting to this step in getting to this solution is starting to look at health economic models that integrate therapeutic costs and savings from development through to long term patent treatment costs.  Together, Canada’s companies, networks, researchers, start-ups and innovative centres are starting to deliver on the promise of regenerative medicine. With the technical know-how and a spirit of collaboration, biomedical engineers are a driving force in the country’s quest to lead the regenerative medicine industry into the future.  +++++  Personalized medicine is becoming a very popular term heard amongst researchers and the scientific community. It is a more tailored approach to preventing disease that is based on an individual’s predispositions. Whichever way you put it – personalized medicine, genomic medicine, precision medicine – it is reshaping healthcare.  Dr. Richard Kim, a scientist at Lawson Health Research Institute and clinical pharmacologist at London Health Sciences Centre (LHSC), has received $4.4 million to study an expanded personalized medicine program at London Health Sciences Centre. One-third of the funding comes from the provincial government’s Ontario Research Fund (ORF) while the remainder is contributions from Thermo Fisher Scientific and donor funding through London Health Sciences Foundation.  Personalized medicine uses pharmacogenomics – the study of genetic changes that alter the way a person responds to individual drugs. The new funding will enable researchers to follow patient outcomes and assess the cost-effectiveness of London Health Sciences Centre’s personalized medicine program, providing evidence on the relationship between the cost of the program and how patient care is improved.  London Health Sciences Centre’s personalized medicine program involves the full integration of research into patient care and was the first in Canada to implement personalized medicine as a clinical strategy. The practice began in 2008 through Dr. Kim’s research on warfarin – a blood thinner prescribed to treat blood clots.  Adverse drug reactions in patients is a significant problem. Some drugs do not metabolize with every patient, and can even lead to toxicity. It is the fourth leading cause of death among hospitalized patients and costs the Canadian health care system over $5 billion a year.  Dr. Kim explains, “For every medication, there are patients who should be prescribed lower or higher than the recommended standard dose and patients who should be prescribed an entirely different medication. Personalized medicine studies a patient’s unique DNA to ensure he or she is prescribed the right dose of the right medication at the right time.”  The team’s research continues to grow since inception and is providing testing for several other drugs. For example, they can now offer testing for cancer patients that have been prescribed 5-fluorouracil – a highly toxic form of chemotherapy – but is integral in treating bowel, stomach, head, and neck cancers.  Oncologists at London Health Sciences Centre’s London Regional Cancer Program can now refer patients to get tested for their potential reaction to 5-fluorouracil to better predict if they may or may not have an adverse reaction. A blood sample will be taken and tested with genotyping, and a full report given to the recommending oncologist. If a patient’s predicted to react poorly with the drug, they can follow clinical guidelines to either reduce the dose or find a method of treatment.  The team will study the outcomes of any patients referred to the program, including hospital stays, emergency department visits, and physician visits. These patients will be compared to others in the province using provincial health care data from the Institute for Clinical Evaluative Sciences (ICES). The team hopes to demonstrate the cost-effectiveness of implementing personalized medicine in a large acute-care hospital in Ontario.  +++++  The most recent announcement from the government of Ontario this past week was that it is investing $50 million in venture capital funds focused on life sciences.  Ontario is moving forward with their plan for a venture capital fund to aid life sciences firms access the capital they need to grow their business, create jobs, and grow on a global level.  The Ontario Capital Growth Corporation (OCGC) would like to identify fund managers to partner with other institutional investors such as corporations, banks and pension funds. Ontario’s new life sciences venture capital fund is designed to respond to the challenges faced in raising capital by innovative, high-potential life sciences companies to scale up and reach global markets.  The Hon. Reza Moridi, Minister of Research and Innovation says, “Providing much needed capital to growing life sciences companies is a crucial step towards a strong and sustainable life sciences ecosystem. Supporting high-potential life sciences companies will create good jobs and help commercialize technologies and services for improved healthcare at home and around the world.”  Ontario’s new venture capital fund focused on life sciences is designed to respond to the challenges faced in raising capital by innovative, high-potential life sciences companies to scale up and reach global markets. It will also help businesses foster new discoveries, including new technologies, treatments and cures for illnesses while supporting high quality, knowledge-based jobs for people across the province. It will also drive Ontario’s ability to attract and retain talent.  The Ontario Capital Growth Corporation, venture capital agency of the government of Ontario, was created to promote and develop the venture capital sector in Ontario, so that more high-potential technology companies have access to the capital needed to grow and prosper.  Supporting innovation in the life sciences is part of Ontario’s plan to create fairness and opportunity during this period of rapid economic change. The plan includes a higher minimum wage and better working conditions, free tuition for hundreds of thousands of students, easier access to affordable child care, and free prescription drugs for everyone under 25 through the biggest expansion of medicare in a generation.  Ontario is the largest life sciences jurisdiction in Canada with more than 50 per cent of overall Canadian revenue. The province includes an incredible 1,840 firms employing close to 61,000 people across the province. This fund will open many doorways for Canadians and Ontarians.   +++++  Well, that wraps up another episode of Biotechnology Focus radio. I hope you enjoyed it. If you have a story idea or would like to be on the show, please email me at press@promotivemedia.ca. To see the articles in full check out the website biotechnologyfocus.ca ca so you don’t miss a beat! Have a momentous week. From my desk to yours – this is Michelle Currie.

This week on the podcast Julie talks to Dr. Jacob McGee, who treats women’s cancers at the London Health Sciences Centre. Jake is also Julie’s doctor, and he has been treating her for ovarian cancer since 2014. Julie wanted to record this podcast with Jake to share the many difficult but important conversations they have had in the past three and a half years, on a subject that affects so many Canadian families – cancer care. In other news, American judge Victoria Pratt's TED Talk on procedural justice is making waves; Julie talks to Australian radio about her work on Islamic divorce; and a Canadian company requests feedback on the costs of family legal disputes. More on this episode on our website: https://representingyourselfcanada.com/lets-talk-about-cancer/

Episode 3 is generously sponsored by start.ca. On this episode: The Transformation of Care Dr. Irene Hramiak, Site Chief of Medicine and the Centre for Diabetes, Endocrinology and Metabolism at St. Joseph’s Health Care London and a Professor and Division Chair at Western's Schulich School of Medecine and Dentistry talks about about how a rebuilding a century-old hospital from the ground up has led to new discoveries and treatments in patient care. Watch some videos about the transformation here. Scanning The Mysteries Dr. Lisa Saksida (twitter), Canada Research Chair in Translational Cognitive Neuroscience Dr. Ravi Menon (twitter), Canada Research Chair in Functional and Molecular Imaging, Medical Director at CFMM (twitter) Dr. Adrian Owen (twitter), Canada Research Excellence Chair in Cognitive Neuroscience at Western University All three exceptional scientists tell us about sixty-six million dollar study that involves, scientists, doctors, musicians, artists, and business people looking into the most mysterious organ we have through BrainsCAN (twitter). Meet Our Future Robot Surgeons Dr. Christopher Schlachta at CSTAR, London Health Sciences Centre is blending virtual reality with real-world robots to make surgery safer, faster, and more accessible. Watch a video about Nick Paparella's experience with robotic surgery.

Why do some city projects cost so much money?Guest: Lloyd Ferguson, Ward 12 councillor-Since the Netflix series "13 Reasons Why" was released, the number of Google searches for topics related to suicide has risen by a drastic amount.Guest: Dr. Paul Links, Chief of Mental Health Services at St. Joseph's Health Care London and London Health Sciences Centre, received of the Canadian Association for Suicide Prevention Research Award for outstanding contributions to the field of suicide research in Canada in 2009-There is concern in the Canadian housing market that the market is beginning to cool, and not only are thousands of jobs at risk, but the value of houses will drop significantly.

Zymeworks, ProMetic Life Sciences, Innovative Targeting Solutions all back in the news again; Saskatchewan researchers make a breakthrough on a devastating pig virus, and healthcare behemoth GE partners with STEMCELL Technologies.We have this and more on this week’s Biotechnology Focus Podcast! Welcome to Biotechnology Focus Podcast. I’m your host Shawn Lawrence. Story 1 We kick things off this week in the prairies, where in less than a year, University of Saskatchewan (U of S) scientists have developed and tested a prototype vaccine that could protect the North American swine industry from a virus that has killed more than eight million pigs and cost more than $400 million in lost income since 2013. The Porcine Epidemic Diarrhea Virus (PEDV) hit the U.S. in 2013 and spread to Canada in 2014. It is a coronavirus, a virus group which includes important emerging human diseases such as SARS and MERS. It was first discovered in Europe, and has become increasingly problematic in Asian countries. Occurring only in pigs, PEDV can kill up to 100 per cent of infected piglets. Using its new containment Level 3 facility, the Universtiy of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) quickly launched a vaccine development project. The project has resulted in a prototype vaccine that protects 100 per cent of the piglets who have received it, according to  Dr. Volker Gerdts, VIDO-InterVac’s research director. The successful vaccine results have since triggered the interest of several animal health companies including Huvepharma, which has partnered with VIDO-InterVac to develop the technology for commercial production in North America. With the support of the swine industry, the vaccine is now undergoing field testing in Saskatchewan, as well as in Manitoba where it is being used to help protect piglets from a recent PEDV outbreak. VIDO-InterVac director Andrew Potter said such a project wouldn’t be possible without this facility, adding that “This is a perfect example of why InterVac was constructed – it is one of the only facilities available internationally with the capacity to conduct vaccine development and testing on this scale for emerging infectious diseases and It helps Canada remain prepared to quickly respond to outbreaks like this,” he said. The PEDV vaccine development project has been supported by a variety of funders including the Government of Saskatchewan (ADF), Sask Pork, and the Canadian Swine Health Network. Story 2 The US Food and Drug Administration (FDA) has given Toronto’s Trillium Therapeutics Inc. the go-ahead to initiate a Phase 1 clinical trial for its lead drug candidate, TTI-621 (SIRPaFc), in solid tumours and mycosis fungoides. Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune system, and the drug is currently being evaluated in an ongoing Phase 1 dose escalation study in patients with relapsed or refractory hematologic malignancies. Patient enrollment in the Phase 1 trial is anticipated to commence by year end. The trial will be multicenter and open-label, with TTI-621 being delivered to patients with relapsed and refractory, percutaneously-accessible cancers by intratumoral injection that increase in dose and dosing frequency to characterize safety, pharmacokinetics, pharmacodynamics and preliminary evidence of antitumour activity. In addition, detailed evaluation of serial, on-treatment tumor biopsies of both injected and non-injected cancer lesions will help characterize tumor microenvironment changes anticipated with CD47 blockade. Story 3 As part of its strategy to leverage and attract investor interest to Québec’s life sciences sector, the Fonds de solidarité FTQ has made a $15 million investment in Genesys Capital’s latest venture fund Genesys Ventures III. The fund itself will used to back companies at the seed-stage, considered by many in the industry the valley of death, to help these companies advance technologies and products for unmet medical needs. Genesys Capital is one of the largest Canadian-based venture capital firms exclusively focused on the life sciences industry. Of note, Knight Therapeutics Inc., a specialized biopharmaceutical company based in Montreal, QC is also committing $1 million to Canadian-based life sciences venture capital fund Genesys Ventures III LP. For Knight the investment is the eighth life sciences equity fund investment Knight has made to date, having committed over $125 million. In terms of the Genesys Ventures III fund, Genesys Capital says it has closed $90 million of its $125 million target for the fund, while Managing director Damian Lamb adds that the firm expects to reach its goal for Genesys Ventures III early next year. Should the fund reach this target, it would be the largest Genesys has raised in its 16-year history. Story 4 Zymeworks is back in the news this week as the United States Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for its lead product ZW25 as a treatment for certain HER2-expressing cancers. ZW25 is a novel bi-specific antibody, developed using the company’s Azymetric™ platform, to target two different epitopes (bi-paratopic targeting) of the human epidermal growth factor receptor 2 (HER2) proteinThe protein is known to be over-expressed on the surface of many tumour types, including certain breast, gastric, lung, and ovarian cancers. ZW25 will be evaluated in the clinic for safety as well as efficacy in patients with tumours with low to moderate levels of HER2 expression. The company anticipates it will begin a Phase 1 clinical trial for ZW25 in late August of this year. Additionally, last week  the FDA granted Orphan Drug Designation to ZW25 and a second product, ZW33 for the treatment of ovarian cancer. ZW33 is a drug-conjugated version of ZW25 that is currently in development in preparation for an IND filing in early 2017. Orphan designation qualifies Zymeworks for a number of development incentives, including tax credits for clinical testing and marketing exclusivity for a period of seven years if ZW25 and/or ZW33 is approved for this indication. Story 5 The Ontario Institute for Cancer Research (OICR), Thermo Fisher Scientific and Queen’s University are collaborating on a research study to help bring more targeted diagnosis and treatment to breast cancer patients in the future. The study, led by Dr. John Bartlett, director of OICR’s Transformative Pathology Program, and Dr. Harriet Feilotter, Department of Pathology and Molecular Medicine, Queen’s University, aims to identify mutations and copy number changes found in breast cancer samples and establish whether these abnormalities correlate with on-market drugs, available clinical trials or published studies. OICR-affiliated researchers and collaborators at Queen’s University and Sunnybrook Health Sciences Centre will process the same breast cancer samples to establish whether the results are reproducible at different sites. This study will also characterize more than 400 additional retrospective breast cancer samples supporting ongoing clinical research efforts of Dr. Bartlett’s team at OICR, which strives to improve the clinical management of the disease. Collaborators Drs. Martin Yaffe and Arun Seth at Sunnybrook Health Sciences Centre will provide laboratory space and additional technical support for the study. Dr. Yaffe is also co-leader of OICR’s Smarter Imaging and Imaging Translation Programs. The study will use Thermo Fisher’s Oncomine Comprehensive Assay, a targeted, next-generation sequencing (NGS) research tool that analyzes 143 genes relevant to cancer and which is the NGS assay used for the NCI-MATCH study in the United States. The data generated can be further studied with the Oncomine Knowledgebase Reporter, which is a curated set of published evidence that matches driver genetic variants with relevant information, such as on-market drugs, available clinical trials, or published studies. The findings of the OICR study will be used to assess the technology and could inform subsequent clinical trials. Drs. Feilotter and Bartlett have also engaged six laboratories in Ontario, including at Hamilton Health Sciences, London Health Sciences Centre, Ottawa General Hospital, Sunnybrook Health Sciences Centre, Sudbury Health Science North and University Health Network to look at the robustness and reproducibility of the assay across different cancer samples. This collaboration could extend the findings of this study beyond breast cancer to other common cancers. Story 6 Vancouver’s Innovative Targeting Solutions has teamed up with yet another major life science company, this time striking a research collaboration deal with Janssen Biotech, Inc. (Janssen), through Johnson & Johnson Innovation.  The deal will allow Janssen to utilize Innovative Targeting Solutions' proprietary HuTARG™ research platform to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer. The HuTARG™ protein engineering platform is able to engineer both T-cell receptors and fully human antibodies that bind major histocompatibility complex (MHC)/peptide complexes displaying fragments of intracellular proteins of interest.  Essentially, it allows researchers to generate and engineer fully human antibodies. The technology underlying the platform is based upon the natural process of V(D)J recombination, employed by the human immune system to produce a diverse repertoire of antibodies. Details of the collaboration including the specific targets, number of targets, and specific therapeutic indications have not yet been disclosed nor have financial details. In June, ITS announced a research collaboration with Merck, to utilize the HuTARG™ research platform to help identify and develop biologic therapeutic candidates directed towards targets that have historically been a challenge for biologic therapies, and just two weeks ago, ITS also partnered with another Vancouver-based company known for its own string of deals with pharma, Zymeworks. Other disclosed ITS collaborators include Novartis and Amgen. Story 7 A few months ago, Biotechnology Focus spoke with Phil Vanek (of GE Healthcare) and Michael May (of CCRM) about BridGE@CCRM, the centre they co-created at the MaRS West Towere to help accelerate the creation of cellular therapeutic tools. Now GE is taking another step in its mission to bring the right infrastructure to the global cell therapy industry, with another unique partnership here in Canada, signing an exclusive licensing agreement with Vancouver-based STEMCELL Technologies Inc., to develop and commercialize cGMP grade versions of STEMCELL’s T-Cell reagents for the isolation, activation, and culture of T-cells in clinical applications. Both parties say these reagents are critical tools in the development and manufacturing of cell and gene therapies intended for administration to patients. The following proprietary reagents from STEMCELL Technologies will be qualified as cGMP-grade materials and licensed by GE Healthcare:  ImmunoCult™ Human CD3/CD28 T-Cell Activator, ImmunoCult™ Human CD3/CD28/CD2 T-Cell Activator, EasySep™ Release Human CD3 Positive Selection Kit and the ImmunoCult™–XF T-Cell Expansion Medium. According to Allen Eaves, president and CEO of STEMCELL Technologies Inc. this partnership with GE will give STI customers the confidence of a path to the clinic with a suite of critical cGMP grade T-cell reagents as well as help the industry evolve and make these promising therapies, such as CAR-T cells and TCR-engineered T cells, a clinical reality. The agreement closely follows GE’s acquisition of Biosafe Group SA, as well as many other investments in the space to make available a turnkey, scalable, flexible manufacturing solution that will enable access to these critical therapies. With that we’ve come to the end of this week’s program. We hope you enjoyed it. A big thanks to our production manager Laskey Hart and the rest of the Biotechnology Focus team. You can find past episodes online at www.biotechnologyfocus.ca and we’re always looking for your feedback, story ideas and suggestions so we’d love to hear from you. Simply reach out to us on twitter: @BiotechFocus  or by email biotechnology_focus@promotive.net. For all of us here at Biotechnology Focus, thank you for listening.

Interview with Dr. Mandar Jog, Director of the National Parkinson Foundation Centre of Excellence at London Health Sciences Centre, Director of the Movement Disorders Program in London, Ontario and Professor of Neurology at Western University. Parkinson disease remains a clinical diagnosis, based on motor symptoms and signs. Dr. Jog discusses what’s new in our understanding and treatment of this common neurodegenerative disorder. He co-authored a review article published in the CMAJ. Full review article (subscription required): www.cmaj.ca/lookup/doi/10.1503/cmaj.151179 ----------------------------------- Subscribe to CMAJ Podcasts on iTunes, Stitcher, Overcast, Instacast, or your favourite aggregator. You can also follow us directly on our SoundCloud page. Our podcasts are also released on www.cmaj.ca and on www.cmajblogs.com.

Dr Palma talks to ecancertv at ASTRO 2015 about the concept of oligometastases and how novel approaches such as stereotactic radiation therapy may be used to treat patients with multiple metastases. In the interview he notes that better evidence is needed to determine which patients may benefit from such an approach and comments on research being conducted by the London Health Sciences Centre in collaboration with the VUmc Cancer Center in Amsterdam.

Dr. Moneeza Walji, editorial fellow, interviews Dr. Amit Garg, nephrologist at London Health Sciences Centre and Professor of Epidemiology and Biostatistics at Western University. Dr. Garg and colleagues found that nitrofurantoin was less effective than other antibiotics for treatment of UTI in a large cohort of older women, regardless of the women’s estimated kidney function. Full article: http://www.cmaj.ca/content/early/2015/04/27/cmaj.150067 Published April 27, 2015, doi: 10.1503/cmaj.150067

Comedian and actor Alan Thicke joins the program to talk about his career and his work with the Alan Thicke Center for Juvenile Diabetes Research. Television audiences know Thicke best as psychiatrist and father Jason Seaver from ABC’s Growing Pains, now syndicated in over 65 countries. Last year’s Growing Pains: The Reunion was one of Disney’s highest-rated TV Movies. From 1980 to 1983, THE ALAN THICKE SHOW became (and remains) the biggest hit in the history of Canadian daytime television. The American late-night entry THICKE OF THE NIGHT followed. Alan is currently starring in CBC Television's monster comedy success J-POD. The Alan Thicke Centre for Juvenile Diabetes Research was established in 1989 at the Robarts Research Institute at the London Health Sciences Centre. The Centre was named for actor Alan Thicke because of his early connection to London while attending The University of Western Ontario, and his special interest in diabetes, as he had a son who developed diabetes as a child